Tumor Biomarkers in Gynecology—2nd Edition
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 508
Special Issue Editors
Interests: gynecology; obstetrics; gynecology oncology; minimally invasive surgery; endocrinology; tumor biomarkers; human papilloma virus
Special Issues, Collections and Topics in MDPI journals
Interests: gynecology; gynecologic oncology; minimally invasive surgery; urogynecology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gynecological cancers frequently affect the female population worldwide. Despite the best efforts of scientists in implementing screening and early diagnosis programs, it is only in cervical cancer that we have been able to identify an effective method of prevention.
In relation to ovarian cancer, the literature has analyzed the well-known markers CA125 and HE4, which are historically reliable, but early-stage diagnosis requires the implementation of more precise biomarkers. Attempts are currently being made to introduce liquid biopsy into early detection to identify promising microRNA biomarkers.
Although it is used in endometrial cancer, the known protein CA-19.9 is imprecise and has been surpassed by HE4; the latter’s clinical utility may be limited by its lower sensitivity, but it is strongly related to prognosis. The new frontier is represented by proteomic biomarkers (e.g., YKL-40, DJ-1) and promising exonal biomarker miRNA (e.g., 21, 27, and 223), showing higher sensitivity and specificity.
In breast cancer, CA15.3 is the best-known tumor marker and is strongly associated with tumor stage. New strategies are also being studied in this field, with a focus on new, more effective markers in the peripheral blood for use in early diagnosis and risk stratification for the development of breast cancer. These markers could include the hypermethylation of cell-free DNA or circular RNAs, and they could prove vital in prognosis and treatment.
Finally, although there was already a reliable screening process for cervical cancer, precision medicine allowed the introduction of the squamous-cell carcinoma (SCC) antigen. New markers are emerging that could increase this biomarker's diagnostic and prognostic potential, possibly associating it with miRNA or the evaluation of long non-coding RNAs.
Therefore, moving forward through this century, our challenge is to identify more effective and accurate biomarkers for the early diagnosis of gynecological cancers.
Dr. Corrado Terranova
Dr. Francesco Plotti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecological cancers
- precision medicine
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issue
- Tumor Biomarkers in Gynecology in Biomedicines (1 article)
